Clinical trials: Lung Atypical Carcinoid Tumor
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back.
- Conditions
- Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma
- Trial name
- NCT03110978
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic).
- Conditions
- Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
- Trial name
- NCT03879694
- Testing
- Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Pulmonary Neuroendocrine Tumor
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen.
- Trial name
- NCT07357623
- Testing
- Surufatinib Combined With Standard chemotherapy, Surufatinib
- Where
- 4 sites in China
- Volunteers
- 96 people
- Sponsor
- Shanghai Chest Hospital